NCT00811174View on ClinicalTrials.gov

Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

PHASE3TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Immunologic Deficiency Syndromes

Interventions

DRUG

Octagam 10%

300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)

Trial Locations (1)

1100

Contact Barbara Pyringer at Octapharma/ Vienna/ Austria for information, Vienna

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Octapharma

INDUSTRY